PresentationOperator Welcome, and thank you for standing by. I would like to inform all participants that this conference call as well as any Q&A may be recorded. Where a company is presenting, any recording may also be posted on their website. Views and opinions expressed by any external speakers on this call are those of the speakers and not of JPMorgan. Parts of this conference call may be reproduced in JPMorgan Research. If you have any objections, you may disconnect at this time. Unless otherwise permi ...

Thermo Fisher Scientific (TMO) Fireside Chat September 05, 2025 01:00 PM ET Company ParticipantsMarc Casper - Chairman, President & CEOConference Call ParticipantsRachel Vatnsdal - Senior Equity Research Analyst - HealthcareOperatorWelcome, and thank you for standing by. I would like to inform all participants that this conference call, as well as any Q&A, may be recorded. Where a company is presenting, any recording may also be posted on their website. Views and opinions expressed by any external speakers ...

医疗健康与工业过滤领域突破 新 增 的 医 疗 设 备 过 滤 解 决 方 案 （ 如 透 析 器 、 呼 吸 机 滤 网 ） 及 工 业 用 高 精 度 过 滤 器 （ 如 半 导 体 制 造 中 的 超 纯 水 处 理 系 统），将帮助赛默飞拓展医疗设备制造商及半导体客户的市场份额。 本土化生产与供应链优化 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2025 年 9 月 3 日 ， 全 球 科 学 仪 器 与 生 命 科 学 服 务 巨 头 赛 默 飞 世 尔 科 技 （ Thermo Fi sher Scientific ） 宣 布 ， 已 以 约 40亿美元现金完成对Sol ventum公司纯化与过滤业务的收购。此次交易标志着赛默飞在生物制药、医疗健康及工业过 滤领域的技术整合迈出关键一步，进一步巩固其在生命科学解决方案市场的领导地位。 Sol ventum的纯化与过滤业务原为3M公司旗下医疗健康部门的核心资产，2024年独立分拆后专注于生物制剂、医疗 设备及工业应用领域的高精度过滤解决方案。该业务2024年营收达10亿美元， ...

2025年9月2日， Solventum（NYSE: SOLV） 宣布已完成将其 净化与过滤（Purification & Filtration, P&F）业务 以 41亿美元（约合人民币292亿） 出售给 Thermo Fisher Scientific（NYSE: TMO） 的交易。这一交易不仅是Solventum独立上市以来最重要的一次资产调整，也是Thermo Fisher在全球生物加工产业链整合中迈出的 关键一步。对双方而言，这笔交易既是资本运作的结果，更是战略选择的体现，对全球医疗与生命科学产业格局也将带来深远影响。 北京和上海活动报名： 第三届全球手术机器人大会 2025医疗器械研发创新论坛 被出售的净化与过滤业务，是Solventum原3M医疗板块的重要组成部分。该业务在医疗技术、生物制药、微电子、食品饮料等多个行业均有应用，尤其在生物制药 制造领域，其过滤与膜技术对于保障药品生产的效率与纯度至关重要。 一 、4 1亿美元 交易 落地 ：过 程与细节 这笔交易最早于2025年2月25日达成协议，并在7月15日获得欧盟委员会批准，最终在9月2日完成，时间进度符合此前设定的"2025年底前交割"的 ...

Investors seemed unhappy about some major spending news from the company.Sprawling medical device and solutions company Thermo Fisher Scientific (TMO -1.22%) wasn't looking all that healthy on Tuesday, at least as far as its stock was concerned. The company closed a pair of acquisitions, and the twin moves didn't seem to make some investors happy. As a result, the stock fell by more than 1%, a slightly steeper drop than the S&P 500's (^GSPC -0.69%) 0.7%. A $4 billion dealOf Thermo Fisher's two transactions, ...

Core Viewpoint - Solventum has successfully completed the sale of its Purification & Filtration business to Thermo Fisher Scientific for $4.0 billion, marking a significant step in its transformation strategy and capital allocation plan [1][2]. Group 1: Transaction Details - The sale was finalized for $4.0 billion in cash, with net proceeds expected to be $3.4 billion after customary adjustments [1][2]. - Solventum plans to primarily use the proceeds to pay down outstanding debt, thereby reducing leverage and enhancing financial flexibility for future investments [2][7]. Group 2: Financial Guidance and Impact - Solventum has updated its full-year 2025 guidance to account for the effects of the P&F divestiture, including a reduction in net interest expense that is anticipated to offset the financial impact of the sale [3][4]. - The company expects organic sales growth in the range of +2.0% to +3.0%, with adjusted EPS increased to a range of $5.88 to $6.03 from a prior range of $5.80 to $5.95 [8]. - Free cash flow is projected to remain stable at $450 million to $550 million, and net interest expense is expected to decrease to $400 million from a previous estimate of $450 million [8]. Group 3: Strategic Focus - The transaction is part of Solventum's three-phased transformation plan aimed at delivering long-term shareholder value and improving operational execution [2][7]. - The company will continue to provide transitional services and perform certain manufacturing and distribution activities for Thermo Fisher post-transaction [4].

摘要 ： 2025上半年国内液质联用仪市场"量额双升"，中标396台/套，金额12.52亿元，高校科研与卫生系统成主力，进口品牌 占主导，国产厂商多点突破加速崛起。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在科技与创新的浪潮中，质谱仪以其独特的技术优势，逐步成为多个领域不可或缺的分析工具。市场数据显示， 2024 年全球质谱仪市场销售额已高达74. 6亿美元 ，预计未来七年还将以6.5%的年复合增长率持续攀升，2031年或将达 到109.1亿美元。 作为质谱仪市场的核心品类，液质联用仪（LC-MS）的发展态势尤为引人注目。仪器信息网基于2025上半年（截至6 月30日）国内液质联用仪公开中标数据的不完全统计，深入剖析市场发展趋势与竞争格局，为行业提供参考依据。 注：本文搜集信息全部来源于网络公开招投标平台，不完全统计分析仅供读者参考。 从 采 购 单 位 类 型 分 析 ， 高 校 科 研 机 构 与 卫 生 系 统 构 成 市 场 " 双 引 擎 " 。 高 校 科 研 以 152 台 / 套 的 采 购 量 （ 占 比 38.4 ...

Core Viewpoint - The "Lai Fu Initiative" was launched by Kexing Group and 70 other companies in the biopharmaceutical sector at the 2025 Supply Chain Ecological Conference, aiming to foster global cooperation in China's health industry and share market opportunities and development benefits [1] Group 1: Industry Trends - The biopharmaceutical industry is undergoing a transformative wave driven by innovation, reshaping the industry landscape and becoming a key force for economic growth and technological innovation [1] - The initiative emphasizes the need for collaborative research platforms to overcome key bottlenecks in drug and vaccine development, promoting shared technological achievements and accelerating product innovation cycles [1] Group 2: Market Opportunities - Industry experts believe that the current uncertainties in the sector may conceal greater opportunities for growth [1] - Kexing Group's CEO highlighted that the integration of biotechnology and AI technology is reshaping health demands and unlocking significant growth opportunities, with China leveraging its 1.4 billion domestic market to establish a global strategy in biotechnology [1]

Key Takeaways Thermo Fisher expands pharma, biotech, and biosciences capacity to support global vaccine demand.TMO's new alliances include a Sanofi site acquisition and a Chan Zuckerberg imaging collaboration.Macroeconomic volatility and rising SG&A costs pressured TMO's margins, while competition remained intense.Thermo Fisher Scientific Inc.’s (TMO) recent slew of strategic collaborations reflects its ongoing commitment to sustainable long-term growth. End markets play an important role as well, bolsterin ...

Core Viewpoint - The Chinese innovative drug industry is rapidly developing under policy support and globalization, with leading companies like BeiGene and HengRui Medicine making significant advancements through high R&D investments and dense pipelines [2][3]. Policy and Market Dynamics - The National Healthcare Security Administration initiated the 2025 medical insurance directory adjustment, emphasizing support for innovative drugs, which has boosted industry confidence [3]. - In the first half of 2025, the transaction amount for Chinese innovative drug BD reached $48.448 billion, highlighting accelerated globalization and international cooperation [3]. Company Performance Overview - **BeiGene**: Achieved revenue of 17.518 billion yuan, a 46% increase year-on-year, with a net profit of 450 million yuan, marking its first profitable half-year since listing. Its core product, Tislelizumab, generated sales of 2.643 billion yuan, up 20.6% [7]. - **HengRui Medicine**: Reported innovative drug sales and licensing income of 9.561 billion yuan, accounting for 60.66% of total revenue, with core innovative drug sales driving growth [8]. - **Hansoh Pharmaceutical**: Revenue reached 7.434 billion yuan, a 14.3% increase, with innovative drug sales contributing 82.7% [8]. - **Innovent Biologics**: Generated over 5.2 billion yuan in product revenue, a growth of over 35%, and completed a significant financing project [8]. - **China National Pharmaceutical Group**: Revenue of 17.57 billion yuan, with a net profit of 3.39 billion yuan, a 140.2% increase year-on-year [8]. - **East China Pharmaceutical**: Achieved revenue of 7.317 billion yuan, a 9.24% increase, with R&D investment rising significantly [9]. R&D Pipeline and Trends - The innovative drug sector is experiencing a concentrated R&D phase, with leading companies accelerating their pipeline development [10]. - **HengRui Medicine**: Six first-class innovative drugs were approved during the reporting period, with a robust pipeline including multiple drugs in various clinical stages [13]. - **BeiGene**: Continues to advance in ADC and bispecific antibodies, enhancing its international competitiveness [13]. - **Innovent Biologics**: Has 52 drugs in clinical stages, focusing on various innovative targets [13]. Role of Scientific Instrumentation - Scientific instrument manufacturers are transitioning from supporters to key enablers in the innovative drug sector, providing comprehensive technical support throughout the drug development process [3][14]. - **Waters Corporation**: Reported an 11% growth in pharmaceutical business, with a 70% increase in GLP-1 related income [15]. - **Agilent Technologies**: Increased revenue in life sciences and diagnostics, establishing strategic partnerships to enhance drug development capabilities [16]. - **Thermo Fisher Scientific**: Achieved $6 billion in laboratory product sales, exceeding market expectations, and providing comprehensive services for drug development [16]. Industry Outlook - The rapid development of new molecular types like antibodies and ADCs is creating significant challenges in quality management, fostering a deep coupling between innovative drug companies and scientific instrument manufacturers [18].